Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home
Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players who have enjoyed success on their own turf will become a global threat.
You may also be interested in...
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.
As “The Pink Sheet” team heads to BIO’s annual partnering convention in Chicago, the Russian government rejects Abbott’s bid for NGO Petrovax. Plus news on deals between Roche and Ascletis, Lilly and Siemens, and Santaris and Bristol-Myers.
HYDERABAD, India - Shantha Biotechnics, the Sanofi-owned Indian vaccines company, has received prequalification by the World Health Organization for a range of vaccines, including the pentavalent Shan 5 vaccine brand that had been previously disqualified by the world agency following detection of impurities in some batches